Brief: Passage Bio Announces Interim Clinical Data From First Eight Patients With GM1 Gangliosidosis

Passage Bio

07/08/2023 15:40

Aug 7 (Reuters) - Passage Bio Inc  PASG.O :
    * PASSAGE BIO INC - ANNOUNCES INTERIM CLINICAL DATA FROM
FIRST
EIGHT PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY
    * PASSAGE BIO - INTERIM SAFETY DATA UP TO 28 MONTHS SHOWED
DOSE 1
& 2 OF PBGM01 WERE WELL TOLERATED AND HAD FAVORABLE SAFETY AND
IMMUNOLOGICAL PROFILE
    * PASSAGE BIO INC - INITIAL SAFETY AND BIOMARKER DATA FROM
DOSE 3
EXPECTED BY MID-2024

Source text for Eikon:  ID:nGNX564Y6t 
Further company coverage:  PASG.O 

 ((Reuters.Briefs@thomsonreuters.com;))